- Diurnal Group, the speciality pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, has successfully dosed the first patient in the company's native oral testosterone formulation (DITEST) phase I clinical trial.

This study will evaluate pharmacokinetics, safety and tolerability of DITEST in the target patient group of males with hypogonadism (Clinical Trials ID NCT02966652).

Chief executive Dr Martin Whitaker said: "The start of this trial is another meaningful step towards achieving Diurnal's vision of becoming one of the world's leading endocrinology speciality pharma companies. DITEST is our next pipeline product to enter clinical development after Infacort and Chronocort, our lead programmes.

"Currently available topical formulations of native testosterone have significant compliance and potential safety issues while, to date, attempts to create oral preparations of modified testosterone have resulted in products with unacceptable pharmacokinetic variability. Therefore, there is an unmet need for an effective oral testosterone treatment for hypogonadism that we believe can be met by our oral proprietary formulation. We look forward to reporting data from this important proof-of-concept study in patients in mid-2017."

Story provided by